TITLE

Research Capsules

PUB. DATE
September 2006
SOURCE
Pharmaceutical Representative;Sep2006, Vol. 36 Issue 9, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the effects and side effects of some medicines in the U.S. Eli Lilly & Co.'s drug Evista may though prevent breast cancer, it may expose women more to stroke. Administration of Meridia, the drug developed by Abbott Laboratories Inc., may help obese adolescents lose weight. Taking the drug Provenge, developed by Dendreon Corp., may provide a survival benefit for men with advanced prostate cancer.
ACCESSION #
22304129

 

Related Articles

  • FDA APPROVES DULOXETINE HCI FOR THE MANAGEMENT OF FIBROMYALGIA. Stoltzfoos, Lonnie // Primary Psychiatry;Jul2008, Vol. 15 Issue 7, p24 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve the duloxetine HCI drug called Cymbalta from Eli Lilly for the management of fibromyalgia. It notes that the approval was based on the results of two three-month clinical trials representing 874...

  • Misleading Medicine. O'Meara, Kelly Patria // Insight on the News;04/30/2001, Vol. 17 Issue 16, p10 

    Reports on the side-effects of the drug Sarafem manufactured by Eli Lilly company. Approval of the United States Food and Drug Administration on the use of Sarafem for female mental disorder; Symptoms of mental disorder; Difference between Sarafem and Prozac drugs.

  • Group aims to cut costs of late-stage drugs. Wall, J. K. // Indianapolis Business Journal;10/1/2012, Vol. 33 Issue 31, p27 

    The article focuses on the collaboration of 10 drug companies in September 2012 including Eli Lilly & Co., AstraZeneca, and Abbott Laboratories to cut costs of late-stage clinical trials.

  • Abbott Spin-Off Continues Health Care Firm Streamlining. Sikora, Martin // Mergers & Acquisitions: The Dealermaker's Journal;Oct2003, Vol. 38 Issue 10, p16 

    Presents updates on corporate reorganizations as of October 2003. Plan of Abbott Laboratories to shed a part of its hospital products business in tax free spin off; Exit of Eli Lilly & Co. from medical devices; Departure of Pfizer Inc. from consumer products.

  • Pharma Posts Mixed 2Q Results.  // Chemical Market Reporter;7/22/2002, Vol. 262 Issue 3, p3 

    Reports the posted earnings of a number of pharmaceutical companies worldwide as of the second quarter of 2002. Impetus to the declined net income of Eli Lilly and Company; Percentage of net profit increase at Pfizer Inc.; Disclosure on the total net profit of Abbott Laboratories.

  • Delay won't stop other Prozac suits. Beaven, Stephen // Indianapolis Business Journal;04/14/97, Vol. 18 Issue 4, p21 

    Focuses on the lawsuits filed against Eli Lilly & Co. related to the alleged violent effect of Prozac, the company manufactures, on psychiatric patients taking the drug in the United States. Background of some of the Prozac cases; Recusal of the judge from the case; Speculation on a secret...

  • High-cost sepsis drug forces pharmacists to weigh patients' future. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/15/2002, Vol. 59 Issue 8, p1 

    Describes how hospital pharmacists in the United States are strategizing the use of drotrecogin alfa, the first pharmaceutical indicated specifically for battling severe sepsis. Approval of Eli Lilly and Co.'s license for drotrecogin alfa activated, or Xigris, in November 2001; Labeling's...

  • Results from cancer trial boost shares of Eli Lilly.  // Indianapolis Business Journal;2/24/2014, Vol. 34 Issue 53, p6 

    The article reports on the increase in the shares of pharmaceutical company Eli Lilly & Co. following the results of the Phase 3 trial of ramucirumab, an anticancer drug, in the U.S.

  • Study Supports Efficacy of Linagliptin.  // Chain Drug Review;6/11/2012, Vol. 34 Issue 10, p70 

    The article reports on the results of the third phase of a study by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. which revealed that five milligrams of linagliptin taken once a day is effective in reducing hemoglobin A1c.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics